OREANDA-NEWS Very soon, the third phase of the clinical trials of an HIV vaccine will begin in Europe and the USA, which includes genetic material from various strains of the virus. It is planned that the vaccine will protect against varieties of HIV than any other existing vaccine. 

It became known that in the United States and Europe in September will begin testing a new vaccine for HIV. It is reported that the vaccine is based on the inactivated cold virus genome, in which three synthetic HIV genes are integrated. These genes were created on the basis of strains identified in several regions of the world. The course of vaccination involves the introduction of four doses of the vaccine. The last two doses are reinforced with synthetic proteins that enhance the production of antibodies against HIV. 

Experts said that the previous steps have already shown their effectiveness. The mosaic vaccine has already triggered an immune response to HIV.